Efficacy and safety of first-ever Dengue vaccine candidate in Phase 3

被引：0
|
作者：
Riedmann, Eva M.
机构：
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2014年 / 10卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：2139 / 2139
页数：1
相关论文
共 50 条
  • [31] Risk of dementia after a first-ever ischemic stroke: A 3-year longitudinal study
    Treves, TA
    Aronovich, BD
    Bornstein, NM
    Korczyn, AD
    CEREBROVASCULAR DISEASES, 1997, 7 (01) : 48 - 52
  • [32] Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
    Hadinegoro, S. R.
    Arredondo-Garcia, J. L.
    Capeding, M. R.
    Deseda, C.
    Chotpitayasunondh, T.
    Dietze, R.
    Ismail, H. I. Hj Muhammad
    Reynales, H.
    Limkittikul, K.
    Rivera-Medina, D. M.
    Tran, H. N.
    Bouckenooghe, A.
    Chansinghakul, D.
    Cortes, M.
    Fanouillere, K.
    Forrat, R.
    Frago, C.
    Gailhardou, S.
    Jackson, N.
    Noriega, F.
    Plennevaux, E.
    Wartel, T. A.
    Zambrano, B.
    Saville, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (13): : 1195 - 1206
  • [33] Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
    Wilder-Smith, Annelies
    Massad, Eduardo
    EXPERT REVIEW OF VACCINES, 2016, 15 (04) : 437 - 441
  • [34] Efficacy of a live attenuated tetravalent candidate dengue vaccine in naive and previously infected cynomolgus macaques
    Koraka, Penelopie
    Benton, Sabrina
    van Amerongen, Geert
    Stittelaar, Koert J.
    Osterhaus, Albert D. M. E.
    VACCINE, 2007, 25 (29) : 5409 - 5416
  • [35] Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus
    Lazo, Laura
    Izquierdo, Alienys
    Suzarte, Edith
    Gil, Lazaro
    Valdes, Iris
    Marcos, Ernesto
    Alvarez, Mayling
    Romero, Yaremis
    Guadalupe Guzman, Maria
    Guillen, Gerardo
    Hermida Cruz, Lisset
    MICROBIOLOGY AND IMMUNOLOGY, 2014, 58 (04) : 219 - 226
  • [36] Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study
    Tricou, Vianney
    Essink, Brandon
    Ervin, John E.
    Turner, Mark
    Escudero, Ian
    Rauscher, Martina
    Brose, Manja
    Lefevre, Inge
    Borkowski, Astrid
    Wallace, Derek
    PLOS NEGLECTED TROPICAL DISEASES, 2023, 17 (03):
  • [37] First ever Hepatitis C vaccine successfully finishes Phase 1 trial
    不详
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) : 3429 - 3429
  • [38] Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials
    Plennevaux, Eric
    Moureau, Annick
    Arredondo-Garcia, Jose L.
    Villar, Luis
    Pitisuttithum, Punnee
    Tran, Ngoc H.
    Bonaparte, Matthew
    Chansinghakul, Danaya
    Coronel, Diana L.
    L'Azou, Maina
    Ochiai, R. Leon
    Toh, Myew-Ling
    Noriega, Fernando
    Bouckenooghe, Alain
    CLINICAL INFECTIOUS DISEASES, 2018, 66 (08) : 1164 - 1172
  • [39] Safety and Protective Efficacy of a Candidate Vector-Based Vaccine for Bovine Tuberculosis
    Abay, Zhandos
    Nurpeisova, Ainur
    Shorayeva, Kamshat
    Sadikaliyeva, Sandugash
    Yespembetov, Bolat
    Syrym, Nazym
    Sarmykova, Makhpal
    Jekebekov, Kuanysh
    Abitayev, Ruslan
    Tokkarina, Gaukhar
    Kalimolda, Elina
    Absatova, Zharkinay
    Moldagulova, Sabina
    Yoo, Han Sang
    Kassenov, Markhabat
    Zakarya, Kunsulu
    Abduraimov, Yergali
    VACCINES, 2023, 11 (07)
  • [40] Outcomes at 3 month after first-ever stroke in Ho Chi Minh City, Vietnam.
    Pham, T. L.
    Blizzard, C. L.
    Srikanth, V.
    Nguyen, L. K. T.
    Nguyen, T. H.
    Gall, S.
    CEREBROVASCULAR DISEASES, 2014, 37 : 288 - 288
12345